While TUBA1C and FBXO17 have been extensively studied in glioma and are known to promote tumor progression, TOM1L1's role in glioma remains underexplored, particularly in the context of PTM‐mediated mechanisms [28, 29]. Here, TUBA1C is linked to neoplasm.